Key result
Serial Lp(a) testing shows considerable variability, with ~36% crossing to high-risk thresholds over 24 months.
Why the study?
Does repeated testing of lipoprotein(a) reveal significant intra-individual variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy?
Observational
Does repeated testing of lipoprotein(a) reveal significant intra-individual variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy?
Answers are grounded in this paper and cite their sources.
Considerable intra-individual variability in Lp(a) levels over 24 months suggests that repeated testing may be warranted for risk stratification and treatment eligibility, challenging the current single lifetime measurement framework.
Although repeated testing of lipoprotein(a) (Lp(a)) is generally not recommended due to the genetically determined nature of concentrations, reports of significant intra-individual variability in serial assessments have challenged the single lifetime measurement framework. Using Lp(a) assessments at baseline, month 12, and month 24 from participants in the REDUCE-IT trial, we identified characteristics that could support repeated testing. Among 386 participants (36.3%) with baseline Lp(a) 50 to <70 mg/dL, 140 (36.3%) had at least one subsequent assessment ≥ 70mg/dL, whereas among 630 participants with baseline Lp(a) ≥ 70mg/dL, 133 (21.1%) had at least one subsequent assessment <70 mg/dL. Baseline Lp(a), sex, race, and several other characteristics were related to variability. Consequently, among individuals at high cardiovascular risk with hypertriglyceridemia and controlled LDL-C on statin therapy, considerable variability was observed over 24 months. These findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.
No takes yet. Share an insight, caveat, or question.
Szarek et al. (2026) conducted an observational in High cardiovascular risk with hypertriglyceridemia and controlled LDL-C on statin therapy. Serial Lipoprotein(a) assessments was evaluated on Subsequent Lp(a) assessment crossing the 70 mg/dL threshold. Serial Lipoprotein(a) assessments over 24 months revealed considerable intra-individual variability, with 36.3% of patients with baseline levels of 50 to </dL crossing to ≥/dL.
Synapse has enriched 10 related papers. Consider them for comparative context: